CoChat
Sign Up
Cited by 248Lipoproteins and Cardiovascular HealthPeripheral Artery Disease ManagementAtherosclerosis and Cardiovascular Diseases

The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST)

Walldius, Göran, Erikson, Uno, Olsson, Anders G., Bergstrand, Lott, Hådell, Karin, Johansson, Jan, Kaijser, Lennart, Lassvik, Claes +5 more·1994·The American Journal of Cardiology
DOI 10.1016/0002-9149(94)90579-7
Open this paper in CoChat — free account

Abstract

The Probucol Quantitative Regression Swedish Trial tested whether treatment of hypercholesterolemic persons with probucol for 3 years affected femoral atherosclerosis. The primary end point was the change in atheroma volume estimated as change in lumen volume of the femoral artery assessed by quantitative arteriography. Three hundred three patients with visible atherosclerosis were randomized to probucol 0.5 g, twice daily, or to placebo. All patients were given diet and cholestyramine, 8 to 16 g/day. Twenty-nine patients were excluded because of inadequate primary end point measurements. The mean age of the remaining 274 subjects (158 were men) was 55 years. Seventeen percent had intermittent claudication and 24% had angina pectoris. After 3 years, the probucol-treated patients had 17% lower serum cholesterol, 12% lower low-density lipoprotein cholesterol, 24% lower total high-density lipoprotein cholesterol, and 34% lower high-density lipoprotein2 cholesterol levels than control subjects. All lipoprotein differences between the treatment groups remained highly significant during the trial. There was no statistically significant change in lumen volume between the probucol and the control group. Furthermore, there was no difference between the treatment groups with regard to change in arterial edge roughness or amount of aorto-femoral atherosclerosis; neither were there any differences between the treatment groups with regard to change in ST-segment depressions on exercise tests or ankle/arm blood pressure (secondary end points). In the control group, lumen volume increased (p < 0.001) and roughness of the femoral artery decreased (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Integrity signals

Registry

Crossref · 10.1016/0002-9149(94)90579-7

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clinically, the suppressive effects of probucol on post-PTCA restenosis, carotid artery IMT progression, and cardiovascular events have been reported from RCTs, albeit small-scale ones.

    “Clinically, the suppressive effects on post-percutaneous transluminal coronary angioplasty (PTCA) restenosis676, 677), carotid artery IMT progression, and cardiovascular events678) have been reported from RCTs, albeit small-scales ones.”

    From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [678]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Walldius, G., Erikson, U., Olsson, A. G., Bergstrand, L., Hådell, K., Johansson, J., Kaijser, L., Lassvik, C., Mölgaard, J., Nilsson, S., Schäfer-Elinder, L., Stenport, G., & Holme, I.
Affiliations
Linköping University (SE)
Corresponding author
Walldius, Göran
ORCID
Olsson, Anders G.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
1994-11
Volume
74
Issue
9
Pages
875-883
ISSN
0002-9149 (ISSN-L)
DOI
10.1016/0002-9149(94)90579-7
OpenAlex
W2131900346
Cited by
248
References
35
Citations by year
2026: 4 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 1 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 2
FWCI
24.90
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The American Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Peripheral Artery Disease Management
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
probucol, femoral atherosclerosis, hypercholesterolemia, atheroma volume, serum cholesterol, lipoproteins, cholestyramine, intermittent claudication, angina pectoris, exercise electrocardiography
MeSH terms
Arteriosclerosis, Cholestyramine Resin, Double-Blind Method, Female, Femoral Artery, Humans, Hypercholesterolemia, Image Processing, Computer-Assisted, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Probucol, Radiography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review